Boehringer Ingelheim registers Phase Ib/II trial pairing obrixtamig, pumitamig in SCLC
A new registry entry outlines a two-cohort study testing obrixtamig with BioNTech's pumitamig, with and without chemotherapy, in extensive-stage small cell lung cancer.
Boehringer Ingelheim registered a new trial listing for a lung cancer combination study, with BioNTech SE as collaborator.
- The Phase Ib/II study, "Dareon®-Rosetta35" (NCT07843940), is an open-label safety and tolerability trial of intravenous obrixtamig in combination with pumitamig and standard of care chemotherapy in patients with extensive-stage small cell lung carcinoma.1 The study is listed as not yet recruiting, with an estimated start date of September 24, 2026.1 It plans to enroll 55 participants across two cohorts, one testing obrixtamig and pumitamig in patients who progressed on prior platinum-based treatment, and another adding carboplatin and etoposide for first-line patients.1 The primary outcome measures treatment-emergent adverse events leading to trial medication discontinuation or dose modification.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.